首页> 外文期刊>Veterinary Surgery >Evaluation of direct in vivo gene transfer in an equine metacarpal IV ostectomy model using an adenoviral vector encoding the bone morphogenetic protein-2 and protein-7 gene.
【24h】

Evaluation of direct in vivo gene transfer in an equine metacarpal IV ostectomy model using an adenoviral vector encoding the bone morphogenetic protein-2 and protein-7 gene.

机译:使用编码骨形态发生蛋白2和7蛋白基因的腺病毒载体评估马掌骨IV骨切除术模型中的直接体内基因转移。

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To evaluate gene transfer in an equine metacarpal IV (MCIV) ostectomy model using adenoviral vectors encoding the human bone morphogenetic protein-2 and protein-7 gene (Ad-BMP-2/-7). Study Design: Experimental Animals Healthy adult horses (n=15). Methods: A plate stabilized, critical size 1.5 cm ostectomy was created in left and right MCIV. The ostectomy site was injected with either Ad-green fluorescent protein (Ad-GFP) or Ad-hBMP-2/-7 at completion of surgery; the same treatment was assigned to both the left and right forelimb of each horse (n=5 horses/group). Bone healing was evaluated radiographically every 2 weeks for 16 weeks. Horses in a pilot study (n=5) were used as untreated controls for radiographic evaluation to 8 weeks. After euthanasia at 16 weeks bone healing was evaluated using dual energy X-ray absorptiometry (DEXA) and histomorphometry. Data were analyzed using an ANOVA or Kruskal-Wallis test. Level of significance was P<.05. Results: At 4 and 6 weeks, the Ad-GFP group had a significantly lower percentage defect ossification compared with the untreated control group. There was no significant difference between untreated and Ad-hBMP-2/-7 groups at any time point and no significant difference in bone healing radiographically, histologically, or using DEXA between any groups at 16 weeks. Conclusions: Ad-hBMP-2/-7 did not improve bone healing in horses at 16 weeks.
机译:目的:使用编码人骨形态发生蛋白2和蛋白7基因(Ad-BMP-2 / -7)的腺病毒载体,评估马掌IV(MCIV)骨切除术模型中的基因转移。研究设计:实验动物健康的成年马(n = 15)。方法:在左侧和右侧MCIV中创建稳定的钢板,临界尺寸为1.5 cm的骨切除术。手术结束时,在骨切除部位注射Ad-绿色荧光蛋白(Ad-GFP)或Ad-hBMP-2 / -7。对每匹马的左前肢和右前肢进行相同的治疗(n = 5马/组)。每2周用放射学评估骨愈合情况,持续16周。一项试验研究中的马(n = 5)被用作未经治疗的对照,以进行放射学评估至8周。安乐死16周后,使用双能X射线吸收法(DEXA)和组织形态学评估了骨愈合。使用方差分析或Kruskal-Wallis检验分析数据。显着性水平为 P <。05。结果:与未治疗的对照组相比,在4周和6周时,Ad-GFP组的骨化率明显降低。在任何时间点,未治疗组和Ad-hBMP-2 / -7组之间无显着差异,在16周时各组之间的影像学,组织学或使用DEXA的骨愈合也无显着差异。结论:Ad-hBMP-2 / -7不能改善16周马匹的骨骼愈合。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号